Using long-range freeze-preventive vaccine carriers in Nepal: A study of equipment performance, acceptability, systems fit, and cost.
AHW, auxiliary health worker
ANM, auxiliary nurse midwife
BPKIHS, B.P. Koirala Institute of Health Sciences
CCH, cold chain handler
Cold chain equipment
FPVC, freeze-preventive vaccine carrier
Freeze-preventive vaccine carrier
HP, health post
Immunization
Innovation
MKT, mean kinetic temperature
MOHP, Ministry of Health and Population
N/A, not applicable
PQS, Performance, Quality and Safety
SVC, standard vaccine carrier
VVM, vaccine vial monitor
Vaccine cold chain
Vaccine freezing
WHO, World Health Organization
Journal
Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
07
05
2021
accepted:
07
02
2022
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
5
3
2022
Statut:
epublish
Résumé
Preventing vaccine freezing is one of the biggest challenges in vaccine management. Until 2018, vaccine carriers used in the immunization program lacked features to prevent vaccine freezing. Freeze-preventive vaccine carriers (FPVCs) have an engineered liner that buffers vaccines from direct exposure to frozen ice packs. A field evaluation of three FPVCs was conducted in 24 health posts in eastern Nepal. The objective was to evaluate the FPVCs' performance, acceptability, systems fit, and cost, to inform prequalification and introduction planning. The study was carried out in two phases: in the first phase, FPVCs containing dummy vaccines (labeled "Not for Human Use") were transported to outreach sessions along with a standard vaccine carrier (SVC); in the second phase, the FPVCs were used for transporting vaccines taken to outreach sessions and used for vaccinating eligible children. The study gathered quantitative and qualitative data from health workers, logbooks, and electronic temperature monitors placed inside and outside the FPVCs. Results indicate the FPVCs successfully prevented temperatures below 0 °C more than 99% of the time-except at one site, where ambient temperatures were below the minimum rated testing temperature specified by the World Health Organization. Internal cool-down times for the FPVCs were highly variable, as were mean kinetic temperatures, possibly driven by the wide range of ambient temperatures and higher-than-expected variations in freezer performance, which, along with the need to transport ice packs to some locations, affected ice-pack temperatures. Almost all health workers requested smaller, lighter-weight FPVCs but appreciated the FPVCs' ability to prevent vaccines from freezing while avoiding undue heat exposure. FPVCs had benefit-cost ratios greater than 1 and hence good value for money. Results point to the importance of understanding the intended environment of use and the need for smaller, short-range as well as long-range carriers.
Identifiants
pubmed: 35243322
doi: 10.1016/j.jvacx.2022.100146
pii: S2590-1362(22)00006-7
pmc: PMC8867128
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100146Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Vaccine. 2007 May 16;25(20):3980-6
pubmed: 17382434
Vaccine. 2018 Jan 2;36(1):128-133
pubmed: 29174313
Vaccine. 2007 Jan 26;25(7):1328-33
pubmed: 17157419
Bull World Health Organ. 2010 Aug 1;88(8):624-31
pubmed: 20680128
Vaccine. 2017 Apr 19;35(17):2127-2133
pubmed: 28364920
Prev Med. 2004 Aug;39(2):384-8
pubmed: 15226050